{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:00:33Z","timestamp":1786410033793,"version":"build-2736575974"},"reference-count":53,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The study objective was to validate febuxostat dosage and administration in pediatric patients with hyperuricemia including gout, using an integrated population pharmacokinetic (PopPK) analysis in the Japanese population. Integrated PopPK analysis of febuxostat used a nonlinear mixed\u2010effects modeling (NONMEM) program on plasma febuxostat concentration data for 2611 samples from Japanese pediatric patients with hyperuricemia including gout (<jats:italic>n<\/jats:italic>\u2009=\u200929) and from adult subjects who are healthy or have renal dysfunction (<jats:italic>n<\/jats:italic>\u2009=\u2009113). We described febuxostat pharmacokinetics using an integrated PopPK model applicable both to pediatric patients and to the adult population. The covariates of body weight and eGFR were identified for CL\/F and the covariate of fasted\/fed status for bioavailability. The range of steady\u2010state exposures (<jats:italic>C<\/jats:italic><jats:sub>max,ss<\/jats:sub> and AUC<jats:sub>\u03c4,ss<\/jats:sub>) for 5, 10, 20, and 30\u2009mg of febuxostat in fed pediatric patients weighing 20 to 40\u2009kg was within that for 10, 20, 40, and 60\u2009mg of febuxostat in fed pediatric patients and adults weighing 40 to 120\u2009kg. Post hoc estimates of CL\/F, adjusted by body weight, differed little between pediatric patients and the adult population in the renal function categories of normal, mild dysfunction, and moderate dysfunction. We successfully validated the febuxostat dose that provided the same level of exposure in pediatric patients as in the adult population: half the adult dose for pediatric patients weighing &lt;40\u2009kg and the full adult dose for pediatric patients weighing \u226540\u2009kg. As in adults, the results support the use of febuxostat without dose adjustment in pediatric patients who have mild to moderate renal dysfunction.<\/jats:p>","DOI":"10.1002\/prp2.70032","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T07:50:13Z","timestamp":1731311413000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1341-7470","authenticated-orcid":false,"given":"Ryutaro","family":"Iwama","sequence":"first","affiliation":[{"name":"Translational Science Research Department Teijin Institute for Bio\u2010medical Research, Teijin Pharma Limited  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimie","family":"Nishida","sequence":"additional","affiliation":[{"name":"Translational Science Research Department Teijin Institute for Bio\u2010medical Research, Teijin Pharma Limited  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishii","sequence":"additional","affiliation":[{"name":"Translational Science Research Department Teijin Institute for Bio\u2010medical Research, Teijin Pharma Limited  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iijima","sequence":"additional","affiliation":[{"name":"Translational Science Research Department Teijin Institute for Bio\u2010medical Research, Teijin Pharma Limited  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d36cc"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d36de"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d351d"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d352f"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31822541d0"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex156"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_15_10_1","first-page":"S1","article-title":"Japanese society of gout and uric & nucleic acids 2019 guidelines for management of hyperuricemia and gout 3rd edition","volume":"44","author":"Hisatome I","year":"2020","journal-title":"Gout and Uric & Nucleic Acids"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_15_12_1","unstructured":"Teijin Pharma.Feburic (febuxostat).2023. Accessed 5 April 2024.https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/470310_3949003F1023_1_17"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200501000-00005"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005282634"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250801956350"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008322035"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31821d36f2"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645080-00005"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010365549"},{"key":"e_1_2_15_20_1","unstructured":"The Electronic Medicines Compendium in the United Kingdom.Adenuric 80 mg film\u2010coated tablets. Summary of product characteristics. Accessed 5 April 2024.https:\/\/www.medicines.org.uk\/emc\/product\/487\/smpc\/print"},{"key":"e_1_2_15_21_1","unstructured":"U.S. Food & Drug administration.ULORIC tablets for oral use. Highlights of prescribing information. Accessed 5 April 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021856s015lbl.pdf"},{"key":"e_1_2_15_22_1","unstructured":"European Medicines Agency.Adenuric 80 mg film\u2010coated tablets. Summary of product characteristics. Accessed 5 April 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/adenuric\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3480718"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02379-0"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-021-03051-x"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1841"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1848"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027377"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027381"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03016.x"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1321847"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2013.1414"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.05.020"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202394"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-01031"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13666"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14357"},{"key":"e_1_2_15_38_1","unstructured":"USA Food and Drug Administration.Uloric (febuxostat). Clinical pharmacology review. NDA 21\u2013856. Accessed 5 April 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000_ClinPharmR_P3.pdf"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000434633"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00943-6"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15462"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2325"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae056"},{"key":"e_1_2_15_44_1","unstructured":"Teijin Pharma.Feburic (febuxostat) Common Technical Document. (In Japanese). Accessed 15 September 2024.https:\/\/www.pmda.go.jp\/drugs\/2011\/P201100023\/index.html"},{"issue":"5","key":"e_1_2_15_45_1","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois D","year":"1989","journal-title":"Nutrition"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12982"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0466-4"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.08.060"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.11.034"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:42:22Z","timestamp":1739266942000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/prp2.70032"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70032","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"2024-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70032"}}